Patent Invalidation Faces Its Biggest Test: Supreme Court To Decide IPR Standard
This article was originally published in The Pink Sheet Daily
Executive Summary
Cuozzo litigation features battle lines familiar from legislation that created inter partes reviews in the first place, with BIO contending the standard for assessing patent claims gives challengers multiple bites at the apple and generic and high-tech companies saying it weeds out weak patents.